Accentia Biopharmaceuticals, Inc, a vertically integrated biopharmaceutical company, announced March 13th that Revimmune™, the company’s potential therapeutic for refractory, relapsing-remitting Multiple Sclerosis (MS). If approved will be the first product capable of restoring neurological function, and has been awarded the Frost & Sullivan Multiple Sclerosis Product Innovation of the Year Award, which is presented to companies in recognition for an outstanding contribution. The Company’s intent is to file an Investigational New Drug Application, with a goal to commence Phase 3 MS clinical trials this year.
Barath Shankar Subramanian, Frost & Sullivan Analyst commented, “The primary endpoint of Accentia’s planned Revimmune Phase 3 study is the restoration of neurological function, which is a paradigm shift from traditional therapies that focus on reducing relapses. Accentia’s innovative positioning and approach to treating autoimmune disease is likely to propel the company as a strong participant in the MS market. In recognition of these factors, Frost & Sullivan is pleased to present Accentia with this Award.”
Revimmune could also help patients utilizing traditional methods by decreasing treatment cost. Revimmune is a one time treatment and cost as opposed to other systems, which represent a lifetime of treatments and costs. Revimmune therapy selectively spares the hematopoetic stem cells, which then regenerate as a new immune system in two to three weeks, potentially eliminating the disease entirely.
Let us hear your thoughts below: